Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
about
Tumor-primed NK cells: waiting for the green lightA Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image CytometryThe narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cellsLow-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II reportGraft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DCA phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cellsEradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.Gene expression analysis of ex vivo expanded and freshly isolated NK cells from cancer patients.Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer CellsEx vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsHigh cell surface death receptor expression determines type I versus type II signalingRevving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.NK cell-based immunotherapies in Pediatric Oncology.Emerging therapies in hematopoietic stem cell transplantationThe novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.Highly activated and expanded natural killer cells for multiple myeloma immunotherapyProteasomal inhibition sensitizes cervical cancer cells to mitomycin C-induced bystander effect: the role of tumor microenvironment.Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewCarfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.Current evidence for histone deacetylase inhibitors in pancreatic cancer.Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancerAdult human sarcomas. II. Medical oncology.Impact of brief exercise on peripheral blood NK cell gene and microRNA expression in young adults.Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccinationPrimitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomibBortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cellsHematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.Productively combining proteasome inhibition with the immunotherapy of cancer.A study exploring critical pathways in clear cell renal cell carcinoma.Expansion and activation of natural killer cells for cancer immunotherapy.Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.Relapse after allogeneic stem cell transplantationTargeting the extrinsic apoptosis signaling pathway for cancer therapy.Use of allogeneic NK cells for cancer immunotherapy.Natural killer cell immune escape in acute myeloid leukemia.
P2860
Q26999306-AF2100A5-E9E8-452F-A165-F02D7828C97DQ27312227-81E5BC68-E5ED-4342-A20C-6ABA9E89A4ACQ33584049-198FE659-6824-4B11-BBA5-A057ECA7ED21Q33744733-E19176AE-5C75-4EA4-B9CF-0445C9D18F12Q33770125-0FAD70C8-9821-4AD8-814D-70531936FCE9Q33940675-2BAEF070-5204-4BFD-8DA0-94FE9F670197Q34241208-03A05FC0-6CCF-4A3F-98EC-CD548E574984Q34605718-814671A9-2C66-4A3B-8433-A61A2467E028Q34652570-40F275E7-103D-4549-86B6-0D9A693FD428Q34985704-F0329D6A-8D56-4521-A24A-B68055929859Q35098303-3DCE7EF7-2A68-43A8-95AA-235F7A8D11EDQ35157421-3C8FFD69-CD6F-483A-84E4-70099A44A6D6Q35371553-9E66615F-DDC0-4BE0-A482-8CEE3CB09392Q35600095-F88C04F3-83D4-4A1C-9198-D19EB6C03831Q35600975-68B20CDB-9CEC-4A3D-8649-1C1FF122D4C0Q35825522-439533E5-9CFF-4097-82DD-C30B328E5A12Q36216192-ACFD25C5-F0E4-4A20-A075-7B6F7B905BD6Q36216203-E46B21A6-8860-4AD0-AA64-2C1181F5004FQ36246486-6A19D29C-CA98-4475-A24B-D900156D872DQ36407085-CD837C32-E925-47B5-951B-E1DCCDA64525Q36408216-F9B233F0-29A3-4008-BA8D-FD8860F1FEA2Q36413676-C3CC2565-F714-42AD-9D06-48E8E832B69BQ36616790-87BC651E-3445-4425-8212-3AB8F74991A0Q36654923-A034BB2F-E3E8-48EC-BCDE-C944019AEA8DQ36709317-D62FBC84-CE0C-4F81-8939-2120F4D9FF3EQ36731430-16A5C71C-3784-4D7D-92FC-1C0799F7120AQ36737701-D6930939-37D8-4CEA-BFC9-DE4DDDBBE7BDQ36874310-CE7FECED-2340-4411-B78C-11B706CBF38BQ37071112-32A22CE7-EDC7-48CD-A24F-11845BEC4DE0Q37160844-876A539F-7CCF-4DDA-8563-FB487509F3AEQ37234615-C275BFD6-AF93-4C36-9675-FFF4B7097754Q37235006-EBBB1E74-FD75-4C74-B6FD-09F9DFCBBE3DQ37348050-9D14D184-1A81-4700-A650-1F43E7CC675CQ37388562-A830F770-EEE7-4AB4-9C38-EAC4E0BC0AF6Q37408279-476DCD75-060E-4086-A059-9EEB98565DA7Q37779043-6A36999F-37A4-40B4-9B4F-77711CD9017DQ37810125-48F5857F-5F6B-4DD6-9118-66763380AAE8Q37882480-1C2B2915-66C1-4765-9AB1-EB4787237894Q37957140-028C47E1-7CDF-43AA-85EF-0C00711AE90DQ37996816-2C4E7DAB-974C-4952-9F93-BC5DD1E25373
P2860
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Bortezomib and depsipeptide se ...... iller cell tumor cytotoxicity.
@en
type
label
Bortezomib and depsipeptide se ...... iller cell tumor cytotoxicity.
@en
prefLabel
Bortezomib and depsipeptide se ...... iller cell tumor cytotoxicity.
@en
P2093
P1433
P1476
Bortezomib and depsipeptide se ...... iller cell tumor cytotoxicity.
@en
P2093
Dante Suffredini
David S Schrump
Gauri Alvarez
Maria Berg
Richard Childs
Scott I Abrams
P304
P356
10.1158/0008-5472.CAN-06-0680
P407
P577
2006-07-01T00:00:00Z